Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 9:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 9,360 matching trials from the live ClinicalTrials.gov search.
Filters: Portland, Oregon Clear all
Completed Phase 3 Interventional Results available

Vitamin D to Improve Outcomes by Leveraging Early Treatment

NCT03096314
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Vitamin D Deficiency, Critical Illness
Interventions
Vitamin D3, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
1,358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
47
States / cities
Fresno, California • Los Angeles, California • Sacramento, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 31, 2026, 9:34 AM EDT
Completed Phase 1 Interventional

Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors

NCT00138216
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
irinotecan hydrochloride, temozolomide, vincristine sulfate
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
16
States / cities
Birmingham, Alabama • Orange, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Oct 31, 2026, 9:34 AM EDT
Completed Phase 3 Interventional Results available

Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia

NCT01401647
View directory record Official record
Conditions
Cardiac Arrest
Interventions
amiodarone, Lidocaine, Normal saline
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
3,024 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
7
States / cities
Birmingham, Alabama • San Diego, California • Portland, Oregon + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 31, 2026, 9:34 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection

NCT05616221
View directory record Official record
Conditions
Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa, Lung Infection
Interventions
AP-PA02, Placebo
Biological · Other
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
23
States / cities
Mobile, Alabama • Los Angeles, California • Farmington, Connecticut + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Oct 31, 2026, 9:34 AM EDT
Completed No phase listed Observational

Gilead Sustained Virologic Response (SVR) Registry

NCT01457755
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Not listed
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
6,625 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
162
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 102 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 31, 2026, 9:34 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone

NCT03738215
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cariprazine, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
65
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 59 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Oct 31, 2026, 9:34 AM EDT
Completed Phase 3 Interventional

Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer Therapy

NCT04538625
View directory record Official record
Conditions
Cancer Therapy-Related Diarrhea, Chemotherapy-related Diarrhea, Adult Solid Tumor, Prophylaxis of Diarrhea, Symptomatic Relief of Diarrhea, Targeted Therapy-related Diarrhea
Interventions
Crofelemer 125 MG [Mytesi], Placebo
Drug
Lead sponsor
Napo Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
27
States / cities
Prescott, Arizona • Anaheim, California • Corona, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2024 · Synced Oct 31, 2026, 9:34 AM EDT
Terminated Phase 2 Interventional Results available

Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma

NCT04527549
View directory record Official record
Conditions
Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Unresectable Melanoma
Interventions
Dabrafenib mesylate, Hydroxychloroquine, Placebo Administration, Trametinib dimethyl sulfoxide
Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
199
States / cities
Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 139 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 31, 2026, 9:34 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Follow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580299) in North America

NCT00546078
View directory record Official record
Conditions
Infections, Papillomavirus
Interventions
Cervarix™
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
15 Years to 25 Years · Female only
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
13
States / cities
San Francisco, California • Augusta, Georgia • Bardstown, Kentucky + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Oct 31, 2026, 9:34 AM EDT
Completed Phase 3 Interventional

Radiation Therapy With or Without Cisplatin or Fluorouracil in Treating Patients With Cancer of the Cervix

NCT00003078
View directory record Official record
Conditions
Cervical Cancer
Interventions
cisplatin, fluorouracil, brachytherapy, radiation therapy
Drug · Radiation
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
870 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
65
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 53 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2013 · Synced Oct 31, 2026, 9:34 AM EDT
Completed Phase 3 Interventional Results available

Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)

NCT00406393
View directory record Official record
Conditions
Leukemia, Myelocytic, Acute, Leukemia, Lymphocytic, Acute, Leukemia, Myeloid, Chronic, Myelodysplastic Syndromes
Interventions
Tacrolimus, Methotrexate, Sirolimus
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
2 Years to 60 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
23
States / cities
Duarte, California • La Jolla, California • Stanford, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Oct 31, 2026, 9:34 AM EDT
Recruiting Phase 3 Interventional

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

NCT06982521
View directory record Official record
Conditions
PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer
Interventions
Zovegalisib, Capivasertib, Fulvestrant
Drug
Lead sponsor
Relay Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
52
States / cities
Gilbert, Arizona • Beverly Hills, California • Duarte, California + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 31, 2026, 9:34 AM EDT
Terminated Phase 3 Interventional Results available

Resuscitation Outcomes Consortium (ROC) Prehospital Resuscitation Using an Impedance Valve

NCT00394706
View directory record Official record
Conditions
Heart Arrest
Interventions
Impedance Threshold Device (ITD), Sham ITD, Analyze early, Analyze later
Device · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
11,738 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
7
States / cities
Birmingham, Alabama • San Diego, California • Portland, Oregon + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 31, 2026, 9:34 AM EDT
Active, not recruiting Phase 1 Interventional

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations

NCT05907304
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors
Interventions
Naporafenib, Trametinib
Drug
Lead sponsor
Erasca, Inc.
Industry
Eligibility
12 Years to 99 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
14
States / cities
San Francisco, California • New Haven, Connecticut • Sarasota, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 31, 2026, 9:34 AM EDT
Recruiting Phase 2 Interventional

KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)

NCT07406633
View directory record Official record
Conditions
GIST - Gastrointestinal Stromal Tumor, GIST, GIST Metastatic Cancer, Gastro Intestinal Stromal Tumour, Gastrointestinal Tumors
Interventions
KQB198, Imatinib (Gleevec)
Drug
Lead sponsor
Kumquat Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
17
States / cities
Los Angeles, California • Jacksonville, Florida • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 31, 2026, 9:34 AM EDT
Completed Phase 2 Interventional Results available

Nesvategrast (OTT166) in Diabetic Retinopathy (DR)

NCT05409235
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
OTT166, Vehicle control
Drug
Lead sponsor
OcuTerra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
67
States / cities
Peoria, Arizona • Phoenix, Arizona • Beverly Hills, California + 59 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 31, 2026, 9:34 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) for Relief of Moderate to Severe Pain in Patients With Osteoarthritis or Low Back Pain Who Require Opioid Treatment for an Extended Period of Time

NCT01240863
View directory record Official record
Conditions
Chronic Pain
Interventions
Hydrocodone ER, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
73
States / cities
Mobile, Alabama • Chandler, Arizona • Scottsdale, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 31, 2026, 9:34 AM EDT
Completed Phase 1Phase 2 Interventional

Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC

NCT00286793
View directory record Official record
Conditions
Prostate Cancer
Interventions
AT-101
Drug
Lead sponsor
Ascenta Therapeutics
Industry
Eligibility
18 Years and older · Male only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
13
States / cities
Hot Springs, Arkansas • Fort Meyers, Florida • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2011 · Synced Oct 31, 2026, 9:34 AM EDT
Terminated Phase 2 Interventional

A Study of the Safety and Efficacy of Multiple Doses of ABT-089 in Subjects With Alzheimer's Disease

NCT00069849
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
ABT-089
Drug
Lead sponsor
Abbott
Industry
Eligibility
50 Years to 85 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
8
States / cities
Fresno, California • San Diego, California • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2006 · Synced Oct 31, 2026, 9:34 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC

NCT03989115
View directory record Official record
Conditions
Solid Tumor
Interventions
RMC-4630, Cobimetinib, Drug: Osimertinib
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
21
States / cities
Scottsdale, Arizona • Duarte, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Oct 31, 2026, 9:34 AM EDT
Completed Phase 4 Interventional Results available

The Dual Antiplatelet Therapy Study (DAPT Study)

NCT00977938
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Placebo & Aspirin, Clopidogrel & Aspirin, Prasugrel & Aspirin
Drug
Lead sponsor
Baim Institute for Clinical Research
Other
Eligibility
18 Years and older
Enrollment
25,682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
178
States / cities
Fairhope, Alabama • Gilbert, Arizona • Phoenix, Arizona + 143 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2017 · Synced Oct 31, 2026, 9:34 AM EDT
Terminated Phase 3 Interventional Results available

A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC

NCT01798485
View directory record Official record
Conditions
Non-Small-Cell Lung Adenocarcinoma, Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Metastatic
Interventions
Docetaxel, Ganetespib
Drug
Lead sponsor
Synta Pharmaceuticals Corp.
Industry
Eligibility
18 Years and older
Enrollment
696 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
78
States / cities
Flagstaff, Arizona • Prescott Valley, Arizona • Sedona, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2016 · Synced Oct 31, 2026, 9:34 AM EDT
Not listed Phase 2Phase 3 Interventional Results available

PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery

NCT01515787
View directory record Official record
Conditions
Colorectal Cancer
Interventions
FOLFOX (chemotherapy), 5 FUCMT (chemoradiation), surgery, magnetic resonance imaging or endorectal ultrasound
Drug · Other · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1,194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
1048
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 613 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2024 · Synced Oct 31, 2026, 9:34 AM EDT
Recruiting Phase 2Phase 3 Interventional

Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study

NCT03373968
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Givinostat
Drug
Lead sponsor
Italfarmaco
Industry
Eligibility
7 Years and older · Male only
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
10
States / cities
Sacramento, California • San Diego, California • Hartford, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 31, 2026, 9:34 AM EDT